


(I);

or a pharmaceutically acceptable salt thereof; and (b) radiation therapy; in amounts effective for treating the brain tumor.


[0012a] In one aspect, there is provided a use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a glioma in a patient in need thereof, wherein the glioma is characterized by the presence of an IDH1 mutation, wherein the IDH1 mutation results in accumulation of R(-)-2-hydroxyglutarate



(I);

wherein a therapeutically effective amount of the compound is to be administered with radiation therapy; wherein said compound of formula (I), or a pharmaceutically acceptable salt thereof, and radiation therapy are to be administered concurrently or wherein said compound of formula (I) is to be administered after radiation.


[0013] In another aspect, the invention provides a method for treating a brain tumor in a patient in need thereof comprising administering to the patient (a) a compound of formula (I)



(I);

or a pharmaceutically acceptable salt thereof; and (b) one or more additional therapeutic agents; in amounts effective for treating the brain tumor.


[0014] In another aspect, the invention provides a method for treating a brain tumor in a patient in need thereof comprising administering to the patient (a) a compound of formula (I)



(I);

CLAIMS

1. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a glioma in a patient in need thereof, wherein the glioma is characterized by the presence of an IDH1 mutation, wherein the IDH1 mutation results in accumulation of R(-)-2-hydroxyglutarate



(I);

wherein a therapeutically effective amount of the compound is to be administered with radiation therapy; wherein said compound of formula (I), or a pharmaceutically acceptable salt thereof, and radiation therapy are to be administered concurrently or wherein said compound of formula (I) is to be administered after radiation.

2. The use of claim 1, wherein said compound of formula (I), or a pharmaceutically acceptable salt thereof, is to be administered once per day in an amount of about 500 mg.

3. The use of claim 1, wherein said radiation therapy is to be administered in the form of x-ray radiation.

4. The use of claim 1, wherein said radiation therapy is to be administered in a cumulative dose of from 30 to 60 Gy.

5. The use of claim 1, wherein the IDH1 mutation is an R132X mutation.

6. The use of claim 5, wherein the IDH1 mutation is an R132H or R132C mutation.

7. The use of any one of claims 1 to 6, wherein said compound of formula (I) is to be administered in non-salt form.